MedTrace Logo

APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer

NCT00709826 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2012-11-07

Study results available
· View outcomes & findings →

Summary

This study will compare the anti-tumor efficacy of apricoxib and gemcitabine/erlotinib with placebo and gemcitabine/erlotinib in patients with advanced pancreatic cancer.

Conditions

Interventions

DRUG

gemcitabine

Gemcitabine: per package insert.

DRUG

placebo

placebo: 100 mg tablets, 400 mg/day

DRUG

Erlotinib

Erlotinib - per package insert.

DRUG

apricoxib

apricoxib: 100mg tablets, given orally

Sponsors & Collaborators

  • Tragara Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Tracy Parrott · Tragara Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-06-30
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00709826 on ClinicalTrials.gov